Go Pro
→ Gold led me to Mount Rushmore (From Stansberry Research) (Ad)tc pixel Free IRMD Stock Alerts

iRadimed (IRMD) Financials

iRadimed logo
$82.22 +0.35 (+0.43%)
Closing price 09/11/2026 04:00 PM Eastern
Extended Trading
$82.12 -0.11 (-0.13%)
As of 09/11/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for iRadimed

Annual Income Statements for iRadimed

This table shows iRadimed's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 7.53 7.21 0.50 6.30 9.63 1.37 9.33 13 17 19 22
Consolidated Net Income / (Loss)		 7.53 7.21 0.50 6.30 9.63 1.37 9.33 13 17 19 22
Net Income / (Loss) Continuing Operations		 7.53 7.21 0.50 6.30 9.63 1.37 9.33 13 17 19 22
Total Pre-Tax Income 		12 11 1.40 6.20 9.04 -0.62 9.84 16 22 24 28
Total Operating Income		 12 11 1.29 6.00 8.65 -0.76 9.82 16 20 22 26
Total Gross Profit		 26 26 18 23 30 24 32 41 50 56 64
Total Revenue		 32 32 23 30 39 32 42 53 66 73 84
Operating Revenue		 32 32 23 30 39 32 42 53 66 73 84
Total Cost of Revenue		 5.84 6.15 5.57 7.21 8.82 8.14 9.76 12 15 17 19
Operating Cost of Revenue		 5.84 6.15 5.57 7.21 8.82 8.14 9.76 12 15 17 19
Total Operating Expenses		 14 15 16 17 21 24 22 26 30 34 38
Selling, General & Admin Expense		 7.77 8.80 9.00 8.71 10 12 9.77 11 15 16 18
Marketing Expense		 4.71 5.28 5.50 7.00 9.17 10 11 13 12 16 17
Research & Development Expense		 1.76 1.35 1.72 1.52 1.43 1.90 1.91 2.28 2.86 2.83 2.98
Total Other Income / (Expense), net		 0.12 0.03 0.11 0.19 0.40 0.14 0.02 0.55 1.70 2.31 2.21
Other Income / (Expense), net		 0.12 0.03 0.11 0.19 0.40 0.14 0.02 0.55 1.70 2.31 2.21
Income Tax Expense		 4.10 3.74 0.90 -0.11 -0.59 -1.99 0.51 3.35 4.55 5.04 5.88
Basic Earnings per Share		 $0.68 $0.67 $0.05 $0.59 $0.85 $0.11 $0.76 $1.02 $1.36 $1.52 $1.77
Weighted Average Basic Shares Outstanding		 11.00M 10.82M 10.64M 10.76M 11.28M 12.12M 12.35M 12.56M 12.60M 12.67M 12.72M
Diluted Earnings per Share		 $0.60 $0.60 $0.04 $0.52 $0.78 $0.11 $0.74 $1.02 $1.35 $1.50 $1.75
Weighted Average Diluted Shares Outstanding		 12.56M 11.99M 11.72M 12.11M 12.28M 12.44M 12.59M 12.64M 12.72M 12.78M 12.85M
Weighted Average Basic & Diluted Shares Outstanding		 11.10M 10.80M 10M 11.00M 11.92M 12.31M 12.56M 12.59M 12.66M 12.72M 12.78M

Quarterly Income Statements for iRadimed

This table shows iRadimed's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Income / (Loss) Attributable to Common Shareholders		 4.54 4.14 4.90 5.05 5.15 4.69 5.77 5.58 6.44 5.82 5.22
Consolidated Net Income / (Loss)		 4.54 4.14 4.90 5.05 5.15 4.69 5.77 5.58 6.44 5.82 5.22
Net Income / (Loss) Continuing Operations		 4.54 4.14 4.90 5.05 5.15 4.69 5.77 5.58 6.44 5.82 5.22
Total Pre-Tax Income 		5.68 5.24 6.27 6.42 6.34 5.95 7.33 7.30 7.79 7.77 6.89
Total Operating Income		 5.16 4.75 5.63 5.79 5.80 5.43 6.79 6.83 7.09 7.24 6.39
Total Gross Profit		 13 13 14 14 15 15 16 16 17 17 15
Total Revenue		 17 18 18 18 19 20 20 21 23 22 20
Operating Revenue		 17 18 18 18 19 20 20 21 23 22 20
Total Cost of Revenue		 4.04 4.21 3.92 4.13 4.63 4.67 4.45 4.71 5.66 5.17 5.31
Operating Cost of Revenue		 4.04 4.21 3.92 4.13 4.63 4.67 4.45 4.71 5.66 5.17 5.31
Total Operating Expenses		 8.25 8.64 8.38 8.40 8.96 9.41 9.17 9.66 9.94 9.58 8.77
Selling, General & Admin Expense		 4.27 3.99 4.10 3.97 3.87 4.61 4.28 4.36 4.54 4.57 3.87
Marketing Expense		 5.54 3.83 3.48 3.80 7.52 4.18 4.01 4.63 4.60 4.05 4.25
Research & Development Expense		 -1.56 0.82 0.80 0.64 -2.44 0.62 0.88 0.67 0.80 0.96 0.66
Total Other Income / (Expense), net		 0.52 0.50 0.64 0.63 0.54 0.51 0.54 0.46 0.70 0.53 0.50
Other Income / (Expense), net		 0.52 0.50 0.64 0.63 0.54 0.51 0.54 0.46 0.70 0.53 0.50
Income Tax Expense		 1.14 1.11 1.37 1.37 1.20 1.26 1.55 1.72 1.35 1.95 1.67
Basic Earnings per Share		 $0.36 $0.33 $0.39 $0.40 $0.40 $0.37 $0.45 $0.44 $0.51 $0.46 $0.41
Weighted Average Basic Shares Outstanding		 12.60M 12.66M 12.66M 12.67M 12.67M 12.71M 12.72M 12.72M 12.72M 12.78M 12.78M
Diluted Earnings per Share		 $0.35 $0.32 $0.38 $0.40 $0.40 $0.37 $0.45 $0.43 $0.50 $0.45 $0.41
Weighted Average Diluted Shares Outstanding		 12.72M 12.75M 12.76M 12.78M 12.78M 12.83M 12.84M 12.86M 12.85M 12.87M 12.87M
Weighted Average Basic & Diluted Shares Outstanding		 12.66M 12.66M 12.67M 12.67M 12.72M 12.72M 12.72M 12.72M 12.78M 12.78M 12.79M

Annual Cash Flow Statements for iRadimed

This table details how cash moves in and out of iRadimed's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 9.91 -1.65 0.49 9.82 15 6.59 12 -4.04 -8.20 2.47 -1.08
Net Cash From Operating Activities		 7.65 9.41 3.42 7.38 10 5.82 11 10 13 26 25
Net Cash From Continuing Operating Activities		 7.65 9.41 3.42 7.38 10 5.82 11 10 13 26 25
Net Income / (Loss) Continuing Operations		 7.53 7.21 0.50 6.30 9.63 1.37 9.33 13 17 19 22
Consolidated Net Income / (Loss)		 7.53 7.21 0.50 6.30 9.63 1.37 9.33 13 17 19 22
Depreciation Expense		 0.81 0.96 1.31 1.11 1.24 1.34 1.41 0.67 0.77 0.82 1.17
Non-Cash Adjustments To Reconcile Net Income		 1.34 2.04 2.75 1.93 1.93 3.90 1.62 1.59 2.61 2.52 2.95
Changes in Operating Assets and Liabilities, net		 -2.03 -0.80 -1.14 -1.97 -2.57 -0.79 -1.07 -5.02 -7.11 3.05 -1.64
Net Cash From Investing Activities		 -0.06 -1.94 -1.02 1.52 3.20 0.25 0.65 -1.37 -8.01 -8.82 -8.42
Net Cash From Continuing Investing Activities		 -0.06 -1.94 -1.02 1.52 3.20 0.25 0.65 -1.37 -8.01 -8.82 -8.42
Purchase of Property, Plant & Equipment		 -0.31 -1.52 -0.82 -0.26 -0.49 -0.64 -0.74 -1.87 -8.01 -8.82 -8.42
Net Cash From Financing Activities		 2.33 -9.12 -1.90 0.93 2.02 0.52 0.02 -13 -14 -14 -18
Net Cash From Continuing Financing Activities		 2.33 -9.12 -1.90 0.93 2.02 0.52 0.02 -13 -14 -14 -18
Payment of Dividends		 - - - - - - 0.00 -13 -13 -14 -15
Other Financing Activities, net		 1.73 0.60 -0.16 0.93 -0.47 -1.21 0.02 -0.15 -0.43 -0.66 -2.56
Cash Income Taxes Paid		 2.70 3.39 1.21 1.38 0.01 0.00 0.97 1.71 5.35 6.51 3.92

Quarterly Cash Flow Statements for iRadimed

This table details how cash moves in and out of iRadimed's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Change in Cash & Equivalents		 3.02 -4.64 3.41 3.19 0.51 -1.90 2.66 3.53 -5.37 5.22 2.71
Net Cash From Operating Activities		 3.91 3.88 6.64 9.12 5.99 4.29 7.75 6.99 5.92 8.29 5.94
Net Cash From Continuing Operating Activities		 3.91 3.88 6.64 9.03 6.08 4.29 7.75 6.99 5.92 8.29 5.94
Net Income / (Loss) Continuing Operations		 4.54 4.14 4.90 5.05 5.15 4.69 5.77 5.58 6.44 5.82 5.22
Consolidated Net Income / (Loss)		 4.54 4.14 4.90 5.05 5.15 4.69 5.77 5.58 6.44 5.82 5.22
Depreciation Expense		 0.21 0.23 0.20 0.20 0.19 0.19 0.21 0.38 0.38 0.46 0.41
Non-Cash Adjustments To Reconcile Net Income		 0.59 0.63 0.74 0.02 1.13 0.77 0.76 0.68 0.73 0.74 0.79
Changes in Operating Assets and Liabilities, net		 -1.42 -1.11 0.80 3.75 -0.40 -1.36 1.00 0.34 -1.63 1.28 -0.48
Net Cash From Investing Activities		 -0.63 -0.48 -1.27 -4.01 -3.06 -3.92 -2.82 -1.26 -0.42 -0.47 -0.44
Net Cash From Continuing Investing Activities		 -0.63 -0.48 -1.27 -4.01 -3.06 -3.92 -2.82 -1.26 -0.42 -0.47 -0.44
Purchase of Property, Plant & Equipment		 -0.63 -0.48 -1.27 -4.01 -3.06 -3.70 -2.82 -1.26 -0.42 -0.40 -0.19
Acquisitions		 - - - - - -0.22 - - - -0.07 -0.26
Net Cash From Financing Activities		 -0.26 -8.04 -1.96 -1.92 -2.42 -2.28 -2.26 -2.19 -11 -2.61 -2.79
Net Cash From Continuing Financing Activities		 -0.26 -8.04 -1.96 -1.92 -2.42 -2.28 -2.26 -2.19 -11 -2.61 -2.79
Payment of Dividends		 - -7.98 -1.90 -1.90 -1.90 -2.16 -2.16 -2.16 -8.55 -2.56 -2.56
Other Financing Activities, net		 -0.26 -0.06 -0.06 -0.02 -0.52 -0.12 -0.10 -0.03 -2.32 -0.05 -0.23
Cash Income Taxes Paid		 1.22 0.19 2.82 1.45 2.06 0.01 2.34 0.15 1.42 0.01 3.37

Annual Balance Sheets for iRadimed

This table presents iRadimed's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 35 37 39 48 67 71 83 86 92 98 109
Total Current Assets		 34 34 35 45 59 64 76 77 76 75 81
Cash & Equivalents		 19 18 18 28 43 50 62 58 50 52 51
Accounts Receivable		 3.86 3.78 3.78 4.21 7.29 4.57 5.14 13 12 11 14
Inventories, net		 2.38 3.89 4.21 4.06 3.64 3.93 4.30 5.37 13 10 12
Prepaid Expenses		 0.32 0.36 0.65 0.53 0.41 0.77 1.00 0.63 1.19 2.05 1.65
Current Deferred & Refundable Income Taxes		 0.42 0.15 0.13 1.37 1.37 2.48 3.31 0.25 - - 3.11
Plant, Property, & Equipment, net		 0.91 1.46 1.87 1.87 2.05 2.12 2.07 2.40 9.29 17 24
Total Noncurrent Assets		 0.39 1.88 2.04 2.03 5.71 5.21 4.57 5.62 6.87 6.27 3.72
Intangible Assets		 0.19 0.92 0.89 0.83 0.86 0.96 1.12 2.07 2.52 3.10 3.38
Noncurrent Deferred & Refundable Income Taxes		 0.09 0.79 0.95 1.09 1.66 1.27 0.77 0.70 2.12 2.82 0.09
Other Noncurrent Operating Assets		 0.10 0.17 0.20 0.11 3.19 2.98 2.68 2.85 2.22 0.35 0.24
Total Liabilities & Shareholders' Equity		 35 37 39 48 67 71 83 86 92 98 109
Total Liabilities		 3.31 5.31 6.08 6.50 11 9.68 11 12 21 12 14
Total Current Liabilities		 2.89 3.66 4.08 4.69 5.86 4.92 6.82 8.55 16 8.51 10
Accounts Payable		 1.01 1.12 0.66 0.77 0.99 0.66 0.78 1.80 1.86 1.90 1.82
Accrued Expenses		 0.03 0.04 0.06 0.07 0.08 0.09 0.11 0.09 0.12 0.12 0.14
Current Deferred Revenue		 0.53 1.03 1.62 1.80 1.67 1.95 2.55 3.37 2.57 2.26 2.87
Current Deferred & Payable Income Tax Liabilities		 - 0.19 0.01 - - - - 0.00 0.25 0.00 1.81
Current Employee Benefit Liabilities		 1.29 1.04 1.51 1.80 2.17 1.71 2.81 2.87 2.78 3.77 3.22
Other Taxes Payable		 0.03 0.12 0.11 0.13 0.60 0.10 0.14 0.12 0.10 - 0.31
Total Noncurrent Liabilities		 0.42 1.64 2.00 1.81 5.35 4.76 3.88 3.29 4.41 3.00 3.98
Noncurrent Deferred Revenue		 0.42 1.64 2.00 1.81 2.63 2.31 1.68 1.38 2.79 2.99 3.98
Total Equity & Noncontrolling Interests		 32 32 33 42 56 61 72 74 71 87 95
Total Preferred & Common Equity		 32 32 33 42 56 61 72 74 71 87 95
Total Common Equity		 32 32 33 42 56 61 72 74 71 87 95
Common Stock		 19 12 13 15 19 24 25 26 28 30 30
Retained Earnings		 13 20 20 27 36 38 47 47 43 57 64

Quarterly Balance Sheets for iRadimed

This table presents iRadimed's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026
Period end date 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026
Total Assets		 76 81 87 88 90 94 102 106 115 114 115
Total Current Assets		 61 66 72 72 74 74 75 77 85 86 87
Cash & Equivalents		 43 46 47 45 49 52 50 53 57 56 59
Accounts Receivable		 12 11 13 13 12 10 13 11 14 13 13
Inventories, net		 6.31 8.42 12 13 12 11 11 11 12 12 12
Prepaid Expenses		 0.68 0.77 0.74 1.04 1.02 0.95 1.54 1.92 1.10 1.63 1.40
Current Deferred & Refundable Income Taxes		 0.00 0.00 0.00 - - - - 0.33 1.70 3.13 0.79
Plant, Property, & Equipment, net		 8.64 8.72 8.89 9.45 10 14 20 23 24 24 24
Total Noncurrent Assets		 5.68 6.62 6.59 6.68 5.90 5.80 6.21 6.14 6.01 3.74 4.05
Intangible Assets		 2.21 2.35 2.46 2.67 2.75 2.89 3.26 3.37 3.37 3.29 3.44
Noncurrent Deferred & Refundable Income Taxes		 0.62 1.77 1.80 1.88 2.59 2.46 2.69 2.56 2.42 0.23 0.36
Other Noncurrent Operating Assets		 2.85 2.50 2.32 2.12 0.56 0.45 0.27 0.20 0.21 0.23 0.24
Total Liabilities & Shareholders' Equity		 76 81 87 88 90 94 102 106 115 114 115
Total Liabilities		 11 12 13 12 10 11 12 12 16 16 13
Total Current Liabilities		 6.76 7.59 7.88 7.62 7.46 8.06 8.47 8.81 13 12 9.16
Accounts Payable		 1.76 2.55 2.78 1.29 1.12 1.40 2.59 1.90 2.33 2.18 1.85
Accrued Expenses		 0.10 0.11 0.11 0.12 0.12 0.12 0.12 0.12 0.14 0.14 0.15
Current Deferred Revenue		 2.07 1.71 1.92 2.34 2.54 2.56 2.60 3.26 3.16 3.40 3.47
Current Deferred & Payable Income Tax Liabilities		 0.49 - - 0.93 0.00 0.00 0.58 - 2.80 3.90 0.00
Current Employee Benefit Liabilities		 1.62 2.33 2.29 2.14 2.90 3.28 2.27 3.21 4.07 2.07 3.06
Other Taxes Payable		 0.06 0.22 0.10 0.14 0.16 0.19 0.26 0.32 0.30 0.43 0.64
Total Noncurrent Liabilities		 4.52 4.85 4.96 4.28 2.82 2.75 3.20 3.33 3.57 3.76 4.06
Noncurrent Deferred Revenue		 2.59 3.01 3.23 2.76 2.82 2.75 3.20 3.33 3.57 3.76 4.06
Total Equity & Noncontrolling Interests		 64 69 75 76 80 83 90 94 98 99 102
Total Preferred & Common Equity		 64 69 75 76 80 83 90 94 98 99 102
Total Common Equity		 64 69 75 76 80 83 90 94 98 99 102
Common Stock		 27 27 28 29 29 30 31 31 32 31 32
Retained Earnings		 37 42 47 47 50 54 59 63 66 67 70

Annual Metrics And Ratios for iRadimed

This table displays calculated financial ratios and metrics derived from iRadimed's official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 - - - - - - - - - - 12,721,156.00
DEI Adjusted Shares Outstanding		 - - - - - - - - - - 12,721,156.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - - - - - 1.77
Growth Metrics		 - - - - - - - - - - -
Profitability Metrics		 - - - - - - - - - - -
Net Operating Profit after Tax (NOPAT)		 7.45 7.19 0.46 6.11 9.21 -0.53 9.31 12 16 17 21
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - - 22.19% 20.05% 21.90%
Earnings before Interest and Taxes (EBIT)		 12 11 1.40 6.20 9.04 -0.62 9.84 16 22 24 28
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 12 12 2.71 7.30 10 0.72 11 17 23 25 30
Valuation Ratios		 - - - - - - - - - - -
Leverage & Solvency		 - - - - - - - - - - -
Liquidity Ratios		 - - - - - - - - - - -
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 6.01 5.95 0.08 5.13 7.50 -0.66 9.04 6.35 1.92 12 12
Efficiency Ratios		 - - - - - - - - - - -
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 4.96 6.21 6.59 7.57 9.27 9.41 9.67 16 30 35 43
Increase / (Decrease) in Invested Capital		 1.44 1.25 0.38 0.98 1.71 0.13 0.27 6.04 14 4.95 8.87
Book Value per Share		 $2.88 $2.98 $3.12 $3.84 $4.83 $5.00 $5.85 $5.86 $5.67 $6.85 $7.44
Tangible Book Value per Share		 $2.87 $2.89 $3.04 $3.76 $4.76 $4.92 $5.76 $5.70 $5.47 $6.61 $7.17
Total Capital		 32 32 33 42 56 61 72 74 71 87 95
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -27 -26 -26 -34 -46 -52 -63 -58 -50 -52 -51
Capital Expenditures (CapEx)		 0.31 1.52 0.82 0.26 0.49 0.64 0.74 1.87 8.01 8.82 8.42
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 4.09 4.52 4.69 5.47 6.85 6.84 6.92 11 9.91 14 20
Debt-free Net Working Capital (DFNWC)		 31 30 31 40 53 59 69 69 60 67 71
Net Working Capital (NWC)		 31 30 31 40 53 59 69 69 60 67 71
Net Nonoperating Expense (NNE)		 -0.08 -0.02 -0.04 -0.20 -0.42 -1.90 -0.02 -0.44 -1.35 -1.83 -1.75
Net Nonoperating Obligations (NNO)		 -27 -26 -26 -34 -46 -52 -63 -58 -42 -52 -51
Total Depreciation and Amortization (D&A)		 0.81 0.96 1.31 1.11 1.24 1.34 1.41 0.67 0.77 0.82 1.17
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.68 $0.67 $0.05 $0.59 $0.85 $0.11 $0.76 $1.02 $1.36 $1.52 $1.77
Adjusted Weighted Average Basic Shares Outstanding		 11.00M 10.82M 10.64M 10.76M 11.28M 12.12M 12.35M 12.56M 12.60M 12.67M 12.72M
Adjusted Diluted Earnings per Share		 $0.60 $0.60 $0.04 $0.52 $0.78 $0.11 $0.74 $1.02 $1.35 $1.50 $1.75
Adjusted Weighted Average Diluted Shares Outstanding		 12.56M 11.99M 11.72M 12.11M 12.28M 12.44M 12.59M 12.64M 12.72M 12.78M 12.85M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 11.03M 10.74M 10.60M 11.00M 11.92M 12.31M 12.56M 12.59M 12.66M 12.72M 12.78M
Normalized Net Operating Profit after Tax (NOPAT)		 7.45 7.19 0.90 4.20 6.05 -0.53 9.31 12 16 17 21
Debt Service Ratios		 - - - - - - - - - - -
Payout Ratios		 - - - - - - - - - - -

Quarterly Metrics And Ratios for iRadimed

This table displays calculated financial ratios and metrics derived from iRadimed's official financial filings.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
DEI Shares Outstanding		 - - - - - - - - 12,721,156.00 12,782,566.00 12,783,035.00
DEI Adjusted Shares Outstanding		 - - - - - - - - 12,721,156.00 12,782,566.00 12,783,035.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - - - 0.51 0.46 0.41
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 17.42% 13.72% 11.15% 11.04% 11.10% 10.87% 13.84% 15.69% - 12.65% 0.28%
EBITDA Growth		 46.78% 20.68% 17.91% 0.26% 11.08% 12.25% 16.49% 16.11% - 33.96% -3.15%
EBIT Growth		 20.79% 20.55% 18.32% 0.15% 11.66% 13.39% 16.88% 13.70% - 30.68% -5.99%
NOPAT Growth		 24.09% 19.38% 12.36% -2.46% 14.13% 14.32% 21.59% 14.66% - 26.55% -9.49%
Net Income Growth		 23.58% 21.45% 17.26% -0.35% 13.37% 13.32% 17.81% 10.44% - 24.13% -9.63%
EPS Growth		 20.69% 18.52% 15.15% 0.00% 14.29% 15.63% 18.42% 7.50% - 21.62% -8.89%
Operating Cash Flow Growth		 28.75% -16.42% 88.93% 554.54% 53.02% 10.53% 16.69% -23.36% - 93.15% -23.33%
Free Cash Flow Firm Growth		 -260.61% 16.66% 35.47% 107.42% 97.49% 21.80% -35.34% -834.80% - 167.54% 172.18%
Invested Capital Growth		 88.61% 43.74% 34.35% 13.98% 16.71% 28.16% 32.66% 31.89% - 6.08% 3.30%
Revenue Q/Q Growth		 5.74% 0.84% 1.88% 2.21% 5.80% 0.63% 4.61% 3.88% - -3.14% -6.88%
EBITDA Q/Q Growth		 -10.78% -7.09% 18.26% 2.28% -1.16% -6.11% 22.72% 1.95% - 0.65% -11.26%
EBIT Q/Q Growth		 -11.34% -7.71% 19.56% 2.38% -1.15% -6.29% 23.24% -0.40% - -0.28% -11.34%
NOPAT Q/Q Growth		 -11.71% -9.14% 17.44% 3.53% 3.31% -8.99% 24.91% -2.37% - -7.61% -10.67%
Net Income Q/Q Growth		 -10.41% -8.88% 18.49% 3.03% 1.93% -8.93% 23.18% -3.42% - -9.69% -10.31%
EPS Q/Q Growth		 -12.50% -8.57% 18.75% 5.26% 0.00% -7.50% 21.62% -4.44% - -10.00% -8.89%
Operating Cash Flow Q/Q Growth		 180.93% -0.75% 70.96% 37.32% -34.32% -28.31% 80.48% -9.81% - 39.97% -28.35%
Free Cash Flow Firm Q/Q Growth		 -9.19% 41.97% 37.36% 118.69% -136.88% -1,710.86% -8.40% -1.49% - 199.83% 15.85%
Invested Capital Q/Q Growth		 6.51% 4.59% 0.46% 1.85% 9.06% 14.86% 3.98% 1.26% - -3.04% 1.25%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 76.86% 76.07% 78.14% 77.44% 76.13% 76.08% 78.17% 77.80% - 76.50% 74.07%
EBITDA Margin		 33.73% 31.08% 36.08% 36.10% 33.73% 31.47% 36.92% 36.23% - 37.42% 35.66%
Operating Margin		 29.57% 26.98% 31.39% 31.59% 29.91% 27.84% 33.26% 32.23% - 32.93% 31.23%
EBIT Margin		 32.56% 29.80% 34.97% 35.02% 32.72% 30.47% 35.90% 34.42% - 35.35% 33.66%
Profit (Net Income) Margin		 26.01% 23.51% 27.34% 27.55% 26.54% 24.03% 28.29% 26.30% - 26.47% 25.50%
Tax Burden Percent		 79.90% 78.89% 78.18% 78.67% 81.12% 78.84% 78.80% 76.42% - 74.89% 75.75%
Interest Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% - 100.00% 100.00%
Effective Tax Rate		 20.10% 21.11% 21.82% 21.33% 18.88% 21.16% 21.20% 23.58% - 25.11% 24.25%
Return on Invested Capital (ROIC)		 68.31% 54.83% 62.78% 59.53% 55.36% 46.65% 56.18% 53.93% - 51.98% 48.65%
ROIC Less NNEP Spread (ROIC-NNEP)		 67.47% 53.94% 61.72% 58.53% 54.42% 45.80% 55.34% 53.28% - 51.23% 47.97%
Return on Net Nonoperating Assets (RNNOA)		 -46.39% -33.75% -39.17% -36.47% -32.33% -26.31% -32.30% -31.72% - -28.99% -27.43%
Return on Equity (ROE)		 21.92% 21.07% 23.61% 23.06% 23.02% 20.34% 23.88% 22.21% - 22.99% 21.22%
Cash Return on Invested Capital (CROIC)		 8.49% 26.72% 33.05% 43.45% 38.78% 26.05% 24.08% 25.70% - 47.51% 47.62%
Operating Return on Assets (OROA)		 24.03% 24.65% 28.35% 27.50% 25.16% 24.14% 28.38% 26.52% - 28.22% 26.25%
Return on Assets (ROA)		 19.20% 19.45% 22.17% 21.63% 20.41% 19.03% 22.37% 20.27% - 21.14% 19.88%
Return on Common Equity (ROCE)		 21.92% 21.07% 23.61% 23.06% 23.02% 20.34% 23.88% 22.21% - 22.99% 21.22%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 23.55% 23.40% 22.33% 0.00% 21.97% 0.00% 0.00% - 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 4.12 3.75 4.40 4.55 4.71 4.28 5.35 5.22 5.87 5.42 4.84
NOPAT Margin		 23.62% 21.29% 24.54% 24.85% 24.27% 21.95% 26.21% 24.63% - 24.66% 23.66%
Net Nonoperating Expense Percent (NNEP)		 0.84% 0.89% 1.06% 1.01% 0.94% 0.85% 0.84% 0.66% - 0.75% 0.67%
Return On Investment Capital (ROIC_SIMPLE)		 5.77% - - - 5.42% 4.76% 5.67% 5.31% 6.20% 5.50% 4.76%
Cost of Revenue to Revenue		 23.14% 23.93% 21.86% 22.56% 23.87% 23.92% 21.83% 22.20% - 23.50% 25.93%
SG&A Expenses to Revenue		 24.49% 22.68% 22.90% 21.65% 19.98% 23.63% 20.97% 20.54% - 20.79% 18.89%
R&D to Revenue		 -8.91% 21.75% 4.47% 3.49% -12.56% 3.20% 4.30% 3.18% - 4.35% 3.21%
Operating Expenses to Revenue		 47.29% 49.09% 46.75% 45.85% 46.21% 48.24% 44.92% 45.56% - 43.57% 42.85%
Earnings before Interest and Taxes (EBIT)		 5.68 5.24 6.27 6.42 6.34 5.95 7.33 7.30 7.79 7.77 6.89
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 5.89 5.47 6.47 6.62 6.54 6.14 7.53 7.68 8.17 8.22 7.30
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 8.27 7.27 6.96 7.64 8.00 7.41 8.06 9.20 - 12.49 12.01
Price to Tangible Book Value (P/TBV)		 8.58 7.53 7.21 7.91 8.30 7.69 8.36 9.53 - 12.92 12.43
Price to Revenue (P/Rev)		 9.01 8.17 7.98 8.94 9.49 8.88 9.79 11.24 - 14.26 14.15
Price to Earnings (P/E)		 34.37 30.87 29.75 34.21 36.13 33.73 36.80 42.71 - 52.11 52.98
Dividend Yield		 3.26% 3.50% 1.44% 1.55% 1.70% 1.18% 1.07% 0.93% - 1.26% 0.77%
Earnings Yield		 2.91% 3.24% 3.36% 2.92% 2.77% 2.97% 2.72% 2.34% - 1.92% 1.89%
Enterprise Value to Invested Capital (EV/IC)		 18.26 16.39 16.25 18.46 18.58 15.53 17.12 20.28 - 27.86 27.24
Enterprise Value to Revenue (EV/Rev)		 8.25 7.51 7.28 8.21 8.78 8.21 9.11 10.54 - 13.61 13.46
Enterprise Value to EBITDA (EV/EBITDA)		 24.04 21.68 20.72 23.95 25.61 23.95 26.36 30.41 - 37.14 37.05
Enterprise Value to EBIT (EV/EBIT)		 24.89 22.45 21.44 24.79 26.48 24.70 27.16 31.52 - 38.90 39.08
Enterprise Value to NOPAT (EV/NOPAT)		 34.15 30.88 29.88 34.80 36.93 34.39 37.44 43.36 - 53.70 54.43
Enterprise Value to Operating Cash Flow (EV/OCF)		 40.18 40.00 31.97 24.86 25.08 23.70 26.06 33.92 - 40.56 42.84
Enterprise Value to Free Cash Flow (EV/FCFF)		 281.19 72.36 56.38 45.27 51.61 66.98 81.09 89.78 - 60.37 58.14
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Financial Leverage		 -0.69 -0.63 -0.63 -0.62 -0.59 -0.57 -0.58 -0.60 - -0.57 -0.57
Leverage Ratio		 1.22 1.17 1.15 1.15 1.20 1.14 1.13 1.15 - 1.15 1.13
Compound Leverage Factor		 1.22 1.17 1.15 1.15 1.20 1.14 1.13 1.15 - 1.15 1.13
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% - 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Altman Z-Score		 19.45 30.51 35.04 37.97 38.82 36.83 40.11 35.64 - 49.09 58.02
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 4.65 9.44 9.87 9.21 8.84 8.87 8.78 6.64 - 7.13 9.46
Quick Ratio		 3.80 7.64 8.11 7.70 7.38 7.44 7.25 5.50 - 5.76 7.89
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -9.80 -5.69 -3.56 0.67 -0.25 -4.45 -4.82 -4.89 -3.01 3.00 3.48
Operating Cash Flow to CapEx		 618.27% 811.01% 522.81% 227.24% 195.87% 109.57% 274.33% 552.89% - 2,057.07% 3,210.81%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.74 0.83 0.81 0.79 0.77 0.79 0.79 0.77 - 0.80 0.78
Accounts Receivable Turnover		 5.14 5.51 6.03 6.16 6.43 5.84 6.79 6.65 - 6.61 7.16
Inventory Turnover		 1.69 1.67 1.55 1.42 1.45 1.49 1.54 1.61 - 1.78 1.78
Fixed Asset Turnover		 11.22 7.48 7.24 6.19 5.61 5.04 4.65 4.24 - 3.87 3.66
Accounts Payable Turnover		 8.43 10.43 8.62 7.79 9.00 8.95 11.84 9.89 - 8.38 11.11
Days Sales Outstanding (DSO)		 70.98 66.22 60.50 59.25 56.76 62.49 53.77 54.91 - 55.25 50.97
Days Inventory Outstanding (DIO)		 215.51 218.72 236.09 256.56 250.90 244.59 237.47 227.27 - 204.89 205.43
Days Payable Outstanding (DPO)		 43.32 35.00 42.33 46.83 40.55 40.77 30.84 36.92 - 43.57 32.84
Cash Conversion Cycle (CCC)		 243.17 249.94 254.26 268.98 267.11 266.31 260.40 245.26 - 216.56 223.56
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 30 31 31 32 35 40 41 42 43 42 43
Invested Capital Turnover		 2.89 2.58 2.56 2.40 2.28 2.13 2.14 2.19 - 2.11 2.06
Increase / (Decrease) in Invested Capital		 14 9.43 7.96 3.89 4.95 8.73 10 10 8.87 2.42 1.36
Enterprise Value (EV)		 541 508 506 585 643 617 707 848 - 1,174 1,162
Market Capitalization		 591 553 555 637 695 667 760 905 - 1,230 1,222
Book Value per Share		 $5.67 $6.01 $6.29 $6.59 $6.85 $7.08 $7.42 $7.74 $7.44 $7.71 $7.96
Tangible Book Value per Share		 $5.47 $5.80 $6.07 $6.36 $6.61 $6.83 $7.15 $7.47 $7.17 $7.45 $7.69
Total Capital		 71 76 80 83 87 90 94 98 95 99 102
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -50 -45 -49 -52 -52 -50 -53 -57 -51 -56 -59
Capital Expenditures (CapEx)		 0.63 0.48 1.27 4.01 3.06 3.92 2.82 1.26 0.42 0.40 0.19
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 9.91 19 18 15 14 16 16 16 20 18 18
Debt-free Net Working Capital (DFNWC)		 60 64 66 66 67 67 69 72 71 74 78
Net Working Capital (NWC)		 60 64 66 66 67 67 69 72 71 74 78
Net Nonoperating Expense (NNE)		 -0.42 -0.39 -0.50 -0.50 -0.44 -0.41 -0.42 -0.35 -0.58 -0.40 -0.38
Net Nonoperating Obligations (NNO)		 -42 -45 -49 -52 -52 -50 -53 -57 -51 -56 -59
Total Depreciation and Amortization (D&A)		 0.21 0.23 0.20 0.20 0.19 0.19 0.21 0.38 0.38 0.46 0.41
Debt-free, Cash-free Net Working Capital to Revenue		 15.12% 28.28% 25.31% 20.34% 19.79% 21.73% 20.05% 19.37% - 20.78% 21.40%
Debt-free Net Working Capital to Revenue		 91.02% 94.95% 95.16% 92.87% 91.11% 88.70% 88.31% 89.58% - 86.12% 89.83%
Net Working Capital to Revenue		 91.02% 94.95% 95.16% 92.87% 91.11% 88.70% 88.31% 89.58% - 86.12% 89.83%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.36 $0.33 $0.39 $0.40 $0.40 $0.37 $0.45 $0.44 $0.51 $0.46 $0.41
Adjusted Weighted Average Basic Shares Outstanding		 12.60M 12.66M 12.66M 12.67M 12.67M 12.71M 12.72M 12.72M 12.72M 12.78M 12.78M
Adjusted Diluted Earnings per Share		 $0.35 $0.32 $0.38 $0.40 $0.40 $0.37 $0.45 $0.43 $0.50 $0.45 $0.41
Adjusted Weighted Average Diluted Shares Outstanding		 12.72M 12.75M 12.76M 12.78M 12.78M 12.83M 12.84M 12.86M 12.85M 12.87M 12.87M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 12.66M 12.66M 12.67M 12.67M 12.72M 12.72M 12.72M 12.72M 12.78M 12.78M 12.79M
Normalized Net Operating Profit after Tax (NOPAT)		 4.12 3.75 4.40 4.55 4.71 4.28 5.35 5.22 5.87 5.42 4.84
Normalized NOPAT Margin		 23.62% 21.29% 24.54% 24.85% 24.27% 21.95% 26.21% 24.63% - 24.66% 23.66%
Pre Tax Income Margin		 32.56% 29.80% 34.97% 35.02% 32.72% 30.47% 35.90% 34.42% - 35.35% 33.66%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 76.91% 44.50% 52.97% 63.22% 71.11% 39.74% 39.33% 39.59% - 65.37% 68.66%
Augmented Payout Ratio		 76.91% 44.50% 52.97% 63.22% 71.11% 39.74% 39.33% 39.59% - 65.37% 68.66%

Financials Breakdown Chart

Key Financial Trends

iRadimed’s financial profile remains profitable and financially healthy, but recent quarterly momentum has moderated. Revenue and earnings have generally expanded since 2022, while the company continues to carry substantial cash and minimal balance-sheet leverage. However, the latest quarter showed sequential declines in revenue, operating income, net income and operating cash flow.

  • Multi-year revenue growth: Quarterly revenue increased from $12.7 million in Q2 2022 to $20.5 million in Q2 2026, representing growth of approximately 61%. Revenue also rose from $16.1 million in Q2 2023 to $20.4 million in Q2 2025 before remaining essentially flat year over year in Q2 2026.
  • Consistent profitability: iRadimed has remained profitable throughout the reported period. Q2 2026 net income was $5.2 million, or $0.41 per diluted share, compared with $3.2 million, or $0.26 per diluted share, in Q2 2022.
  • Strong cash generation: Operating cash flow was positive in every quarter provided, including $5.9 million in Q2 2026. Cash flow from operations has generally exceeded net income, indicating that reported earnings have been supported by cash generation.
  • Large cash position and low leverage: Cash and equivalents reached $59.1 million at June 30, 2026, up from $45.1 million at March 31, 2024. Total liabilities were only $13.2 million, compared with $101.7 million of equity, leaving the company with significant financial flexibility and no reported debt balance.
  • Solid liquidity: Q2 2026 current assets of $86.7 million substantially exceeded current liabilities of $9.2 million. The resulting current ratio was approximately 9.5, providing a considerable cushion for working-capital needs and near-term obligations.
  • Shareholder returns remain a priority: iRadimed paid approximately $2.6 million in dividends in both Q1 and Q2 2026. Retained earnings continued to increase, reaching $70.2 million at the end of Q2 2026 despite the ongoing dividend payments.
  • Margins remain high but have softened: Q2 2026 gross margin was approximately 74.1%, compared with 79.7% in Q2 2022. Operating margin was about 31.2%, below the 32.7% reported in Q2 2022 but still indicative of a highly profitable business.
  • Capital investment has varied: Capital expenditures were $185,000 in Q2 2026, down sharply from $2.8 million in Q2 2025 and $3.7 million in Q1 2025. Lower spending supports near-term free cash flow, but investors should determine whether the reduced investment reflects completion of prior projects or a slower expansion plan.
  • Latest-quarter sequential slowdown: Q2 2026 revenue declined 6.9% from Q1 2026, while operating income fell 11.7% and net income dropped 10.3%. Revenue was also nearly flat year over year, suggesting that the strong growth seen in earlier periods has temporarily lost momentum.
  • Operating cash flow weakened year over year: Q2 2026 operating cash flow of $5.9 million declined from $7.7 million in Q2 2025 and $8.3 million in Q1 2026. The change in operating assets and liabilities was a $478,000 use of cash in Q2, reversing the $1.0 million benefit recorded in Q2 2025.

Overall, the statements show a company with durable profitability, substantial liquidity and a shareholder-friendly dividend policy. The primary issue for investors is whether iRadimed can resume revenue growth and stabilize margins after the softer Q2 2026 results. Comparisons should also be made carefully because several historical income statement and cash flow periods in the supplied data are identified as restated.

09/12/26 03:54 PM ETAI Generated. May Contain Errors.

iRadimed Financials - Frequently Asked Questions

According to the most recent income statement we have on file, iRadimed's fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

iRadimed's net income appears to be on an upward trend, with a most recent value of $22.48 million in 2025, rising from $7.53 million in 2015. The previous period was $19.23 million in 2024. Check out iRadimed's forecast to explore projected trends and price targets.

iRadimed's total operating income in 2025 was $26.15 million, based on the following breakdown:
  • Total Gross Profit: $64.32 million
  • Total Operating Expenses: $38.18 million

Over the last 10 years, iRadimed's total revenue changed from $31.59 million in 2015 to $83.81 million in 2025, a change of 165.3%.

iRadimed's total liabilities were at $14.16 million at the end of 2025, a 23.0% increase from 2024, and a 327.6% increase since 2015.

In the past 10 years, iRadimed's cash and equivalents has ranged from $17.71 million in 2016 to $62.00 million in 2021, and is currently $51.16 million as of their latest financial filing in 2025.

Over the last 10 years, iRadimed's book value per share changed from 2.88 in 2015 to 7.44 in 2025, a change of 157.8%.


Related Companies

Financial statements for NASDAQ:IRMD last updated on 7/31/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Why I'm NOT Buying the SpaceX IPO (And What I'm Buying Instead)
Don't buy Nvidia... Not when the AI companies that will define the next decade are selling for pennies. You wo...
Decentralized Masters | Sponsoredtc pixel
Print this before your next trade
Bill Poulos is offering his Smart Trade Options Checklist at no cost today - normally priced at $29.97. It'...
Profits Run | Sponsoredtc pixel
This 38 Dollar Fund Holds Every Major AI Stock and Pays Weekly
The biggest AI stocks like Nvidia, CrowdStrike, and Palantir now trade for hundreds of dollars a share. One fu...
Investors Alley | Sponsoredtc pixel
The retirement stock I'd buy before Nvidia today
In 2014, Marc Chaikin pointed readers toward Nvidia. Now the 60-year Wall Street veteran and creator of the Ch...
Chaikin Analytics | Sponsoredtc pixel
Why major institutions are piling into this digital asset now
BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...
Awesomely | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
Three companies about to leapfrog Nvidia [And transform the entire industry]
Three under-the-radar companies are already building the infrastructure behind a 200 billion government-backed...
Eagle Publishing | Sponsoredtc pixel
ACTION TAKERS WANTED : Big Elon Opportunity
James Altucher says an FCC filing points to Elon Musk's next major venture, one he believes could dwarf Tesla ...
Paradigm Press | Sponsoredtc pixel